nomacopan (rVA576) for Thrombotic Microangiopathies
Study Summary
This trial is testing a new medication to treat a complication from stem cell transplants in children.
- Thrombotic Microangiopathies
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 4 Secondary · Reporting Duration: 28 weeks
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
nomacopan (rVA576)
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: nomacopan (rVA576) · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age < 65 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 13th, 2021
Last Reviewed: November 24th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.